NVCT (Nuvectis Pharma) EBIT: $-28.27 Mil (TTM As of Mar. 2026)


NVCT Nuvectis Pharma Inc NVCT
22 GF Score
Price $25.42
! 2 Warning Signs
View Full Analysis

What is Nuvectis Pharma EBIT?

Nuvectis Pharma NVCT -8.79% 22 EBIT is $-28.27 Mil as of Mar. 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Nuvectis Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-6.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-28.27 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nuvectis Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was -375.02%. Nuvectis Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nuvectis Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4.35%.

Nuvectis Pharma  (NAS:NVCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nuvectis Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-25.04 * ( 1 - 0% )/( (6.907 + 6.447)/ 2 )
=-25.04/6.677
=-375.02 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=31.709 - 6.389 - ( 31.634 - max(0, 13.296 - 31.709+31.634))
=6.907

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=25.398 - 4.731 - ( 25.13 - max(0, 11.178 - 25.398+25.13))
=6.447

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Nuvectis Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-25.04/( ( (0 + max(-13.221, 0)) + (0 + max(-10.91, 0)) )/ 2 )
=-25.04/( ( 0 + 0 )/ 2 )
=-25.04/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.074999999999999) - (6.389 + 0 + 6.907)
=-13.221

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.268) - (4.731 + 0 + 6.447)
=-10.91

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nuvectis Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-28.266/649.149
=-4.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvectis Pharma EBIT Related Terms

Nuvectis Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Nuvectis Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvectis Pharma EBIT Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -12.89 -19.23 -22.90 -19.85 -27.57

Nuvectis Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.57 -6.60 -7.79 -7.62 -6.26

NVCT vs ALXO, TARA, CNTX: EBIT Comparison

For the Biotechnology subindustry, Nuvectis Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's EV-to-EBIT falls into.


NVCT
22GF Score
Nuvectis Pharma Inc NVCT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvectis Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-28.27 Mil mean?
Nuvectis Pharma (NVCT) has a EBIT of $-28.27 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nuvectis Pharma.
Is Nuvectis Pharma's EBIT too high?
Nuvectis Pharma's current EBIT is $-28.27 Mil. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's EBIT compare to ALXO and TARA?
Nuvectis Pharma's EBIT of $-28.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nuvectis Pharma. Nuvectis Pharma's current EBIT is $-28.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current EBIT of $-28.27 Mil. The current EBIT is $-28.27 Mil. Nuvectis Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current EBIT is $-28.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvectis Pharma Business Description

Address 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score

Get the complete analysis for NVCT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.42
Price